ライフサイエンスコーパス: Kaposi's sarcoma

1 d herpesvirus (KSHV), the etiologic agent of Kaposi's sarcoma.

2 homas, multicentric Castleman's disease, and Kaposi's sarcoma.

3 ovarian, breast, and lung cancer, as well as Kaposi's sarcoma.

4 ly induces angiogenic tumor resembling human Kaposi's sarcoma.

5 elated malignancies, including lymphomas and Kaposi's sarcoma.

6 of vGPCR-induced lesions that resemble human Kaposi's sarcoma.

7 Castleman's disease, as well as its namesake Kaposi's sarcoma.

8 9, 95% CI 1.67-1.72), AIDS-defining cancers (Kaposi's sarcoma [498.11, 477.82-519.03], non-Hodgkin ly

9 mmaherpesvirus etiologically associated with Kaposi's sarcoma, a vascular tumor of endothelial cells.

10 SHV) is the cause of aggressive AIDS-related Kaposi's sarcoma (AIDS-KS) characterized by abnormal ang

11 erpesvirus 8 (HHV-8), the causative agent of Kaposi's sarcoma and B cell neoplasms in AIDS patients,

12 ssociated herpesvirus (KSHV) is the cause of Kaposi's sarcoma and body cavity lymphoma.

13 s tightly associated with the development of Kaposi's sarcoma and multicentric Castleman's disease, a

14 tients at the Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic infections (GHESKIO)

15 several AIDS-related malignancies, including Kaposi's sarcoma and primary effusion lymphoma (PEL).

16 herpesvirus (KSHV), the etiological agent of Kaposi's sarcoma and primary effusion lymphoma, has deve

17 sarcoma-associated herpesvirus (KSHV) causes Kaposi's sarcoma and primary effusion lymphoma.

18 a beneficial component for the treatment of Kaposi's sarcoma and the role of antivirals for HHV-8 in

19 herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma, and a constitutively active viral G pr

20 Kaposi's sarcoma associated herpesvirus (KSHV) establish

21 Human herpes virus 8 (HHV-8), also known as Kaposi's sarcoma associated herpesvirus (KSHV), is an on

22 G, and panel), Epstein-Barr Virus (EBV), and Kaposi's Sarcoma-associated Herpes Virus (KSHV) in a fin

23 Kaposi's sarcoma-associated herpes virus (KSHV) is the c

24 Kaposi's sarcoma-associated herpes virus (KSHV) polyaden

25 B-cell lymphoma associated with infection by Kaposi's sarcoma-associated herpes virus (KSHV).

26 Kaposi's sarcoma-associated herpesvirus (KSHV [human her

27 r maturation of RRV, the closest relative of Kaposi's sarcoma-associated herpesvirus (KSHV) (a human

28 protein (SCP) of human tumor herpesviruses--Kaposi's sarcoma-associated herpesvirus (KSHV) and Epste

29 Kaposi's sarcoma-associated herpesvirus (KSHV) and Epste

30 ame 50 (ORF50) DNA template in the genome of Kaposi's sarcoma-associated herpesvirus (KSHV) and has b

31 Two closely related gammaherpesviruses, Kaposi's sarcoma-associated herpesvirus (KSHV) and rhesu

32 Kaposi's sarcoma-associated herpesvirus (KSHV) and the c

33 Kaposi's sarcoma-associated herpesvirus (KSHV) and the c

34 lytic cycles of Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are induc

35 DNA tumor viruses such as Kaposi's sarcoma-associated herpesvirus (KSHV) are known

36 Using the dimeric protease (Pr) from Kaposi's sarcoma-associated herpesvirus (KSHV) as a mode

37 maherpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) cause lif

38 ive stages of the KSHV life cycle.IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) causes AI

39 Kaposi's sarcoma-associated herpesvirus (KSHV) causes Ka

40 Kaposi's sarcoma-associated herpesvirus (KSHV) causes tw

41 ent SCFAs stimulate lytic gene expression of Kaposi's sarcoma-associated herpesvirus (KSHV) dose depe

42 Human Kaposi's sarcoma-associated herpesvirus (KSHV) effective

43 Kaposi's sarcoma-associated herpesvirus (KSHV) encodes 1

44 Kaposi's sarcoma-associated herpesvirus (KSHV) encodes 1

45 Kaposi's sarcoma-associated herpesvirus (KSHV) encodes 1

46 Kaposi's sarcoma-associated herpesvirus (KSHV) encodes m

47 Kaposi's sarcoma-associated herpesvirus (KSHV) encodes n

48 Kaposi's sarcoma-associated herpesvirus (KSHV) encodes t

49 encoded by open reading frame 36 (ORF36) of Kaposi's sarcoma-associated herpesvirus (KSHV) enhances

50 Kaposi's sarcoma-associated herpesvirus (KSHV) enters hu

51 Latent Kaposi's sarcoma-associated herpesvirus (KSHV) episomes

52 Kaposi's sarcoma-associated herpesvirus (KSHV) establish

53 Kaposi's sarcoma-associated herpesvirus (KSHV) establish

54 Kaposi's sarcoma-associated herpesvirus (KSHV) evades ho

55 We have previously discovered that Kaposi's sarcoma-associated herpesvirus (KSHV) evades th

56 The human oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) expresses

57 Kaposi's sarcoma-associated herpesvirus (KSHV) expresses

58 inity tagged and purified all 89 proteins of Kaposi's sarcoma-associated herpesvirus (KSHV) from huma

59 Lytic activation of Kaposi's sarcoma-associated herpesvirus (KSHV) from late

60 ous transcription across the entirety of the Kaposi's sarcoma-associated herpesvirus (KSHV) genome an

61 e found that most transcripts encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV) genome un

62 Latent Kaposi's sarcoma-associated herpesvirus (KSHV) genomes e

63 y focal assembly of RNA polymerase II around Kaposi's sarcoma-associated herpesvirus (KSHV) genomes i

64 The maintenance of latent Kaposi's sarcoma-associated herpesvirus (KSHV) genomes i

65 ected cells.IMPORTANCE B cells infected with Kaposi's sarcoma-associated herpesvirus (KSHV) harbor mu

66 Kaposi's sarcoma-associated herpesvirus (KSHV) has a cau

67 Kaposi's sarcoma-associated herpesvirus (KSHV) has a sig

68 Kaposi's sarcoma-associated herpesvirus (KSHV) has been

69 Kaposi's sarcoma-associated herpesvirus (KSHV) has been

70 Oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) has laten

71 Kaposi's sarcoma-associated herpesvirus (KSHV) has tropi

72 Here, we report that the Kaposi's sarcoma-associated herpesvirus (KSHV) immediate

73 we present an innovative approach to culture Kaposi's sarcoma-associated herpesvirus (KSHV) infected

74 d levels of viral lytic gene expression when Kaposi's sarcoma-associated herpesvirus (KSHV) infected

75 Kaposi's sarcoma-associated herpesvirus (KSHV) infection

76 was undertaken to determine whether de novo Kaposi's sarcoma-associated herpesvirus (KSHV) infection

77 an effective small-animal model to study the Kaposi's sarcoma-associated herpesvirus (KSHV) infection

78 L) is a lymphogenic disorder associated with Kaposi's sarcoma-associated herpesvirus (KSHV) infection

79 Kaposi's sarcoma-associated herpesvirus (KSHV) infection

80 Kaposi's sarcoma-associated herpesvirus (KSHV) infection

81 lar RNA degradation enzyme Xrn1 during lytic Kaposi's sarcoma-associated herpesvirus (KSHV) infection

82 mined the expression of the DDR genes during Kaposi's sarcoma-associated herpesvirus (KSHV) infection

83 The development of a mouse model for Kaposi's sarcoma-associated herpesvirus (KSHV) infection

84 Kaposi's sarcoma-associated herpesvirus (KSHV) infection

85 Kaposi's sarcoma-associated herpesvirus (KSHV) infects m

86 Latent DNA replication of Kaposi's sarcoma-associated herpesvirus (KSHV) initiates

87 Kaposi's sarcoma-associated herpesvirus (KSHV) interacts

88 The K15P membrane protein of Kaposi's sarcoma-associated herpesvirus (KSHV) interacts

89 The entry of Kaposi's sarcoma-associated herpesvirus (KSHV) into huma

90 Kaposi's sarcoma-associated herpesvirus (KSHV) is a DNA

91 The ORF45 protein of Kaposi's sarcoma-associated herpesvirus (KSHV) is a gamm

92 Kaposi's sarcoma-associated herpesvirus (KSHV) is a gamm

93 Kaposi's sarcoma-associated herpesvirus (KSHV) is a gamm

94 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

95 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

96 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

97 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

98 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

99 Kaposi's sarcoma-associated herpesvirus (KSHV) is a huma

100 Kaposi's sarcoma-associated herpesvirus (KSHV) is a prom

101 Kaposi's sarcoma-associated herpesvirus (KSHV) is an onc

102 Kaposi's sarcoma-associated herpesvirus (KSHV) is associ

103 Kaposi's sarcoma-associated herpesvirus (KSHV) is causat

104 The K1 gene product of Kaposi's sarcoma-associated herpesvirus (KSHV) is encode

105 Kaposi's sarcoma-associated herpesvirus (KSHV) is etiolo

106 Kaposi's sarcoma-associated herpesvirus (KSHV) is etiolo

107 Kaposi's sarcoma-associated herpesvirus (KSHV) is etiolo

108 Kaposi's sarcoma-associated herpesvirus (KSHV) is etiolo

109 Kaposi's sarcoma-associated herpesvirus (KSHV) is linked

110 Kaposi's sarcoma-associated herpesvirus (KSHV) is linked

111 Kaposi's Sarcoma-associated herpesvirus (KSHV) is mainta

112 Latent infection by Kaposi's sarcoma-associated herpesvirus (KSHV) is requir

113 Co-infection with HIV-1 and Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

114 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

115 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

116 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

117 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

118 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

119 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

120 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

121 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

122 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

123 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

124 Kaposi's sarcoma-associated herpesvirus (KSHV) is the ca

125 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

126 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

127 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

128 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

129 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

130 Kaposi's sarcoma-associated herpesvirus (KSHV) is the et

131 lytic phases.IMPORTANCE The K15P protein of Kaposi's sarcoma-associated herpesvirus (KSHV) is though

132 Lytic activation of the cancer-causing Kaposi's sarcoma-associated herpesvirus (KSHV) is vital

133 Kaposi's sarcoma-associated herpesvirus (KSHV) K13/vFLIP

134 The Kaposi's sarcoma-associated herpesvirus (KSHV) LANA prot

135 Kaposi's sarcoma-associated herpesvirus (KSHV) latency a

136 We show that the Kaposi's sarcoma-associated herpesvirus (KSHV) latency l

137 Kaposi's sarcoma-associated herpesvirus (KSHV) latency-a

138 HV68) ORF73 (mLANA) has sequence homology to Kaposi's sarcoma-associated herpesvirus (KSHV) latency-a

139 Specific regions of Kaposi's sarcoma-associated herpesvirus (KSHV) latent ep

140 Kaposi's sarcoma-associated herpesvirus (KSHV) latent ge

141 at the constitutive AMPK activity restricted Kaposi's sarcoma-associated herpesvirus (KSHV) lytic rep

142 Kaposi's sarcoma-associated herpesvirus (KSHV) maintains

143 Sequence comparisons to human Kaposi's sarcoma-associated herpesvirus (KSHV) miRNAs re

144 DSBs) in DNA, although detail concerning how Kaposi's sarcoma-associated herpesvirus (KSHV) modulates

145 egy of selectively isolating VLVs by using a Kaposi's sarcoma-associated herpesvirus (KSHV) mutant th

146 Previously, we showed that the Kaposi's sarcoma-associated herpesvirus (KSHV) NEC speci

147 Spontaneous lytic reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV) occurs at

148 The Kaposi's sarcoma-associated herpesvirus (KSHV) open read

149 ere, we identify a viral trimeric complex of Kaposi's sarcoma-associated herpesvirus (KSHV) open read

150 The Kaposi's sarcoma-associated herpesvirus (KSHV) open read

151 The Kaposi's sarcoma-associated herpesvirus (KSHV) ORF36 pro

152 Although Kaposi's sarcoma-associated herpesvirus (KSHV) ORF52 (al

153 We report here that Kaposi's sarcoma-associated herpesvirus (KSHV) ORF52, an

154 The Kaposi's sarcoma-associated herpesvirus (KSHV) ORF57 gen

155 Kaposi's sarcoma-associated herpesvirus (KSHV) ORF57 pla

156 report that PABPC1 forms a complex with the Kaposi's sarcoma-associated herpesvirus (KSHV) ORF57 pro

157 The Kaposi's sarcoma-associated herpesvirus (KSHV) ORF57 pro

158 Kaposi's sarcoma-associated herpesvirus (KSHV) ORF6 is h

159 ncy-associated nuclear antigen (LANA) of the Kaposi's sarcoma-associated herpesvirus (KSHV) performs

160 ORF59 of Kaposi's sarcoma-associated herpesvirus (KSHV) plays an

161 nprecedented mechanism of viral replication: Kaposi's sarcoma-associated herpesvirus (KSHV) stably cl

162 recently showed that the interaction between Kaposi's sarcoma-associated herpesvirus (KSHV) tegument

163 ed to murine gammaherpesvirus 68 (MHV68) and Kaposi's sarcoma-associated herpesvirus (KSHV) that esta

164 e kinase A2 (EphA2) is an entry receptor for Kaposi's sarcoma-associated herpesvirus (KSHV) that is e

165 sociated substrate) as a platform to promote Kaposi's sarcoma-associated herpesvirus (KSHV) trafficki

166 Here we map the 3' UTRs of Kaposi's sarcoma-associated herpesvirus (KSHV) using nex

167 o-electron microscopy (cryo-EM) structure of Kaposi's sarcoma-associated herpesvirus (KSHV) virion, a

168 rophoretic response of B cells infected with Kaposi's sarcoma-associated herpesvirus (KSHV) were inve

169 e expression occurs upon superinfection with Kaposi's sarcoma-associated herpesvirus (KSHV), a common

170 Kaposi's sarcoma-associated herpesvirus (KSHV), a DNA tu

171 We report that ORF10 of Kaposi's sarcoma-associated herpesvirus (KSHV), a nuclea

172 iral FLICE-like inhibitor protein (vFLIP) of Kaposi's sarcoma-associated herpesvirus (KSHV), against

173 Kaposi's sarcoma-associated herpesvirus (KSHV), also kno

174 ncy is an integral part of the life cycle of Kaposi's sarcoma-associated herpesvirus (KSHV), an etiol

175 V1) lineage consists of human herpesvirus 8, Kaposi's sarcoma-associated herpesvirus (KSHV), and clos

176 osely related to human herpesvirus 8 (HHV-8)/Kaposi's Sarcoma-associated herpesvirus (KSHV), and it i

177 the replication of the oncogenic herpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV), by targe

178 , an immediate-early and tegument protein of Kaposi's sarcoma-associated herpesvirus (KSHV), causes s

179 n adaptive immunity, many viruses, including Kaposi's sarcoma-associated herpesvirus (KSHV), have evo

180 othelial cells during de novo infection with Kaposi's sarcoma-associated herpesvirus (KSHV), in cells

181 aherpesviruses, Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), is assoc

182 The human gammaherpesvirus, Kaposi's sarcoma-associated herpesvirus (KSHV), is tight

183 egument proteins of herpesviruses, including Kaposi's sarcoma-associated herpesvirus (KSHV), play key

184 50 promoters of Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), respecti

185 Kaposi's sarcoma-associated herpesvirus (KSHV), the caus

186 rld primates and are distinct but related to Kaposi's sarcoma-associated herpesvirus (KSHV), the etio

187 Kaposi's sarcoma-associated herpesvirus (KSHV), the etio

188 Kaposi's sarcoma-associated herpesvirus (KSHV), the etio

189 on lymphoma (PEL) cells infected with latent Kaposi's sarcoma-associated herpesvirus (KSHV), the prom

190 (RFHVMn), the pig-tailed macaque homolog of Kaposi's sarcoma-associated herpesvirus (KSHV), was dete

191 viral OX2 (vOX2) immunoregulator encoded by Kaposi's sarcoma-associated herpesvirus (KSHV), we have

192 maherpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), which ar

193 For oncogenic viruses such as Kaposi's sarcoma-associated herpesvirus (KSHV), which is

194 factor in the development and progression of Kaposi's sarcoma-associated herpesvirus (KSHV)-induced p

195 Kaposi's sarcoma-associated herpesvirus (KSHV)-related m

196 n by HIV-1 promotes the aggressive growth of Kaposi's sarcoma-associated herpesvirus (KSHV)-related m

197 erous proliferation of B cells, is caused by Kaposi's sarcoma-associated herpesvirus (KSHV).

198 vo infection of primary endothelial cells by Kaposi's sarcoma-associated herpesvirus (KSHV).

199 hundreds of genes during the reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV).

200 form of aggressive B cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV).

201 nown inflammation related diseases caused by Kaposi's sarcoma-associated herpesvirus (KSHV).

202 for lifelong persistence and pathogenesis of Kaposi's sarcoma-associated herpesvirus (KSHV).

203 Kaposi's sarcoma-associated herpesvirus (KSHV, also call

204 We recently showed that Kaposi's sarcoma-associated herpesvirus (KSHV, or human

205 The responsible agent, Kaposi's sarcoma-associated herpesvirus (KSHV; HHV8), ex

206 16) recognizes nuclear episomal herpesvirus (Kaposi's sarcoma-associated herpesvirus [KSHV], Epstein-

207 Similarly, Kaposi's sarcoma-associated herpesvirus also did not sti

208 Unique to gamma-herpesviruses, like Kaposi's sarcoma-associated herpesvirus and Epstein-Barr

209 Kaposi's sarcoma-associated herpesvirus and rhesus macaq

210 ich tumor cells are consistently infected by Kaposi's sarcoma-associated herpesvirus and usually grow

211 view the evidence for Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus as causal lympho

212 c mechanisms by which Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus cause B-cell lym

213 tors (e.g., herpes simplex virus nectin1 and Kaposi's sarcoma-associated herpesvirus EphA2), or assoc

214 IL-4 also reactivated human Kaposi's sarcoma-associated herpesvirus from latency in

215 Microbe, Chang and Ganem (2013) report that Kaposi's sarcoma-associated herpesvirus infection of lym

216 Kaposi's sarcoma-associated herpesvirus is a leading cau

217 Kaposi's sarcoma-associated herpesvirus is the causative

218 s, the cofactor activity (CFA), by using the Kaposi's sarcoma-associated herpesvirus RCA homolog Kapo

219 t HIV, together with a transient increase in Kaposi's sarcoma-associated herpesvirus viral load at we

220 73 transcript and the MHV68 ORF63 homolog of Kaposi's sarcoma-associated herpesvirus vNLRP1.

221 ciated polyomavirus, Epstein-Barr virus, and Kaposi's sarcoma-associated herpesvirus, because GEMs ha

222 ovirus (HCMV), Epstein-Barr virus (EBV), and Kaposi's sarcoma-associated herpesvirus, establish laten

223 ose relative of the human oncogenic pathogen Kaposi's sarcoma-associated herpesvirus, ORF52 is a high

224 genomes, those of human cytomegalovirus and Kaposi's sarcoma-associated herpesvirus, revealing trans

225 be infected with the human pathogens, EBV or Kaposi's sarcoma-associated herpesvirus, we have used a

226 d from a newly established and characterized Kaposi's sarcoma-associated herpesvirus- and Epstein-Bar

227 Kaposi's sarcoma-associated herpesvirus-encoded vFLIP K1

228 Kaposi's sarcoma-associated herpesvirus-encoded viral FL

229 EL clinical samples, and three extracavitary Kaposi's sarcoma-associated herpesvirus-positive solid l

230 ted with one of oncogenic viruses infection, Kaposi's sarcoma-associated herpesvirus.

231 the organization of this protein complex for Kaposi's sarcoma-associated herpesvirus.

232 rcoma (KS) is a multicentric tumor caused by Kaposi's sarcoma-associated herpesvirus.

233 a 50 years ago, only one other virus, namely Kaposi's sarcoma-associated herpesvirus/human herpesviru

234 omolog, the oncogenic human gammaherpesvirus Kaposi's sarcoma-associated herpesvirus/human herpesviru

235 s an oncogenic gamma-herpesvirus that causes Kaposi's sarcoma, Castleman's disease and primary effusi

236 sal agent of several malignancies, including Kaposi's sarcoma, commonly found in immunocompromised pa

237 Conjunctival Kaposi's sarcoma developed in 1 patient.

238 d herpesvirus (KSHV), the causative agent of Kaposi's sarcoma, encodes 25 mature viral miRNAs.

239 In lymphomas the Epstein-Barr virus (EBV), Kaposi's sarcoma herpesvirus (KSHV) and human T-lymphotr

240 mutant with prototype foamy virus (PFV) and Kaposi's sarcoma herpesvirus (KSHV) tethering sequences

241 fied infections by Epstein-Barr virus (EBV), Kaposi's sarcoma herpesvirus (KSHV), and human T-lymphot

242 Epstein-Barr virus (EBV) and Kaposi's sarcoma herpesvirus (KSHV), formally designated

243 an T cell lymphotropic virus-1 (HTLV-1), and Kaposi's sarcoma herpesvirus (KSHV).

244 ttings and the significant burden exacted by Kaposi's sarcoma in these areas, we reviewed data regard

245 ART has had a substantial impact on Kaposi's sarcoma incidence in resource-rich settings, bu

246 reviewed data regarding the impact of ART on Kaposi's sarcoma incidence.

247 ow that HHV-8, a DNA tumor virus that causes Kaposi's sarcoma, infects three types of dendritic cells

248 Kaposi's sarcoma is a highly vascular tumor, and recentl

249 Kaposi's sarcoma is a highly vascularized, endothelial c

250 Kaposi's sarcoma is one of the most common malignancies

251 Therefore, an understanding of the burden of Kaposi's sarcoma (KS) and non-Hodgkin lymphoma (NHL) rel

252 al and B cells are etiologically linked with Kaposi's sarcoma (KS) and primary effusion B-cell lympho

253 ked to several human malignancies, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

254 irus (KSHV) is etiologically associated with Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

255 virus (KSHV)-related malignancies, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

256 Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

257 several AIDS-related malignancies, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL

258 erpesvirus (KSHV) is the causative agent for Kaposi's sarcoma (KS) and two other lymphoproliferative

259 Kaposi's sarcoma (KS) as the most common AIDS-associated

260 Kaposi's sarcoma (KS) is a disease of multifocal vascula

261 Purpose Kaposi's sarcoma (KS) is a multicentric tumor caused by

262 Kaposi's sarcoma (KS) is an AIDS-defining cancer with ab

263 Kaposi's sarcoma (KS) is common in Africa, but economic

264 High prevalence of Kaposi's sarcoma (KS) is seen in diabetic patients.

265 m multicentric Castleman's disease (MCD) and Kaposi's sarcoma (KS) lesions, suggesting that pERP1 may

266 Of interest, treatment of Kaposi's sarcoma (KS) patients with rapamycin provided t

267 herpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma (KS), a vascular tumor frequently found

268 of care for patients with HIV diagnosed with Kaposi's sarcoma (KS), but the current role of systemic

269 d herpesvirus (KSHV), the etiologic agent of Kaposi's sarcoma (KS), is present in the predominant tum

270 a human gammaherpesvirus casually linked to Kaposi's sarcoma (KS), multicentric Castleman's disease

271 irus (KSHV) is etiologically associated with Kaposi's sarcoma (KS), primary effusion lymphoma (PEL),

272 rpesvirus 8) is linked to the development of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL),

273 neoplastic or lymphoproliferative diseases: Kaposi's sarcoma (KS), primary effusion lymphoma (PEL),

274 herpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma (KS), the most common tumor of AIDS pat

275 ssociated herpesvirus (KSHV) is the cause of Kaposi's sarcoma (KS), which is the most common AIDS-ass

276 Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) infe

277 Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) is a

278 ed by next-generation sequence analysis of a Kaposi's sarcoma (KS)-like macaque tumor.

279 pesvirus (KSHV) is the etiological agent for Kaposi's sarcoma (KS).

280 tential risk factors for development of oral Kaposi's sarcoma (KS).

281 ed herpesvirus (KSHV)-induced posttransplant Kaposi's sarcoma (KS).

282 (MCD), and the inflammation-driven neoplasm Kaposi's sarcoma (KS).

283 nes, which contribute to the pathogenesis of Kaposi's sarcoma (KS).

284 cally associated with the angioproliferative Kaposi's sarcoma (KS).

285 (KSHV), is an oncogenic virus that can cause Kaposi's sarcoma (KS).

286 herpesvirus (KSHV) is the etiologic agent of Kaposi's sarcoma (KS).

287 of immunocompromised individuals, including Kaposi's sarcoma (KS).

288 ncluding primary effusion lymphoma (PEL) and Kaposi's sarcoma (KS).

289 e infected with human herpesvirus 8 (HHV-8) (Kaposi's sarcoma [KS]-associated herpesvirus) and have a

290 ual men were over-represented among men with Kaposi's sarcoma (OR, 48.2; 95% CI, 22.0 to 105.6), anal

291 ting it as a contributor to virus-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and m

292 virus 8 (HHV-8) infection is associated with Kaposi's sarcoma, primary effusion lymphoma (PEL), and m

293 nd angiogenic activities to HHV-8-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and m

294 (KSHV) has been linked to the development of Kaposi's sarcoma, primary effusion lymphoma, and multice

295 ant lymphoproliferative disorders (PTLD) and Kaposi's sarcoma remain important complications of immun

296 lated diagnoses, oesophageal candidiasis and Kaposi's sarcoma, rose from almost zero to very high lev

297 rs.IMPORTANCE KSHV is the etiologic agent of Kaposi's sarcoma, the most common tumor of AIDS patients

298 al role in the initiation and progression of Kaposi's sarcoma tumors.

299 decreased significantly across 1996-2012 for Kaposi's sarcoma, two subtypes of non-Hodgkin lymphoma,

300 s etiologically associated with all forms of Kaposi's sarcoma worldwide.